Article Versions Notes

Just KS, Scholl C, Boehme M, Kastenmüller K, Just JM, Bleckwenn M, Holdenrieder S, Meier F, Weckbecker K, Stingl JC. Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)–Never Change a Running System? Pharmaceuticals. 2021; 14(10):1056. https://doi.org/10.3390/ph14101056

Just, Katja S., Catharina Scholl, Miriam Boehme, Kathrin Kastenmüller, Johannes M. Just, Markus Bleckwenn, Stefan Holdenrieder, Florian Meier, Klaus Weckbecker, and Julia C. Stingl. 2021. "Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)–Never Change a Running System?" Pharmaceuticals 14, no. 10: 1056. https://doi.org/10.3390/ph14101056

Just, K. S., Scholl, C., Boehme, M., Kastenmüller, K., Just, J. M., Bleckwenn, M., Holdenrieder, S., Meier, F., Weckbecker, K., & Stingl, J. C. (2021). Individualized versus Standardized Risk Assessment in Patients at High Risk for Adverse Drug Reactions (The IDrug Randomized Controlled Trial)–Never Change a Running System? Pharmaceuticals, 14(10), 1056. https://doi.org/10.3390/ph14101056